Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02245828 | A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374 | PHASE1 | COMPLETED | 66 | — | — | Jul 1, 2014 | Dec 1, 2015 | Mar 22, 2016 | 1 | United Kingdom |
Number of Participants with Adverse Events
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo comparator |
| QCC374 | EXPERIMENTAL | Single and multiple ascending doses of QCC374 |
| Name | Type | Description |
|---|---|---|
| QCC374 | DRUG | Single and multiple ascending doses of QCC374 |
| Placebo | DRUG | Placebo comparator |
Inclusion Criteria: 1. Written informed consent must be obtained before any assessment is performed. 2. Healthy male and female subjects age 18 to 55 years of age included, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory...